TY - JOUR
T1 - Efficacy of lixisenatide in patients with type 2 diabetes
T2 - A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
AU - Yabe, Daisuke
AU - Ambos, Anu
AU - Cariou, Bertrand
AU - Duvnjak, Lea
AU - Evans, Marc
AU - González-Gálvez, Guillermo
AU - Lin, Jay
AU - Nikonova, Elena V.
AU - de Pablos-Velasco, Pedro
AU - Yale, Jean François
AU - Ahrén, Bo
PY - 2016/10
Y1 - 2016/10
N2 - Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect . P .
AB - Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect . P .
KW - Antidiabetic drug
KW - Beta cell
KW - GLP-1 analog
KW - Glycemic control
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84971657481&partnerID=8YFLogxK
U2 - 10.1016/j.jdiacomp.2016.05.018
DO - 10.1016/j.jdiacomp.2016.05.018
M3 - Article
C2 - 27267268
AN - SCOPUS:84971657481
SN - 1056-8727
VL - 30
SP - 1385
EP - 1392
JO - Journal of Diabetes and its Complications
JF - Journal of Diabetes and its Complications
IS - 7
ER -
